Initial characteristics and follow-up of patients with a diagnosis of angiotensin-converting enzyme inhibitor induced angioedema
- PMID: 35317893
- DOI: 10.2500/aap.2022.43.220005
Initial characteristics and follow-up of patients with a diagnosis of angiotensin-converting enzyme inhibitor induced angioedema
Abstract
Background: A differential diagnosis between angiotensin-converting enzyme inhibitor (ACEi) angioedema (AE) and histaminergic AE (hAE) might be challenging. Follow-up data may help discriminate these conditions but are scarcely reported. Objective: To report on the follow-up of patients with suspected ACEi-AE and to describe the baseline characteristics of AE attacks in patients with a diagnosis of ACEi-AE after follow-up. Methods: Sixty-four patients with suspected ACEi-AE (i.e., with exposure to ACEi before the first attack, no urticaria associated, and normal C1-inhibitor levels) and at least one follow-up visit were included. Data were retrospectively collected at baseline and during the follow-up. Results: After the follow-up, the diagnosis of ACEi-AE was probable in only 30 patients. The remaining patients were reclassified as having probable hAE (21 patients) or undetermined-mechanism AE (13 patients). Patients with ACEi-AE were mostly men (61%), with a median age of 64 years (interquartile range [IQR] ±17 years), with a highly variable delay from ACEi introduction (median: 23 months; interquartile range: 103 months). Attacks preferentially involved lips (50%), tongue (47%), and throat (30%). Interestingly, patients with probable ACEi-AE after a follow-up also frequently presented with a history of allergy and atopic conditions (20%), attacks with preferential evening onset (25%), and spontaneous resolution in < 24 hours (26%), which are usually considered as suggestive of hAE. ACEi-AE attacks responded to icatibant in 79% of the patients. Conclusion: Patients with probable ACEi-AE were mostly men with facial involvement. A third of the patients with an initial suspected diagnosis of ACEi-AE had a final diagnosis of probable hAE. Although a follow-up of all patients should be a standard of care, it is critical to the correct diagnosis in the case of suspected bradykinin-associated AE, which may actually be due to histamine.
Comment in
-
Long-COVID and loss of smell: A post-COVID olfactory dysfunction that continues to challenge the allergist/immunologist.Allergy Asthma Proc. 2022 Mar 1;43(2):93-95. doi: 10.2500/aap.2022.43.220008. Allergy Asthma Proc. 2022. PMID: 35317885 Free PMC article. No abstract available.
Similar articles
-
ACE inhibitor-mediated angioedema.Int Immunopharmacol. 2020 Jan;78:106081. doi: 10.1016/j.intimp.2019.106081. Epub 2019 Dec 10. Int Immunopharmacol. 2020. PMID: 31835086 Review.
-
Angioedema: etiology, pathophysiology, current and emerging therapies.J Emerg Med. 2013 Nov;45(5):789-96. doi: 10.1016/j.jemermed.2013.03.045. Epub 2013 Aug 29. J Emerg Med. 2013. PMID: 23992848 Review.
-
Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.J Clin Pharm Ther. 2019 Oct;44(5):685-692. doi: 10.1111/jcpt.12997. Epub 2019 Jul 9. J Clin Pharm Ther. 2019. PMID: 31290163 Review.
-
[Increasing incidence of angioedema without urticaria--clinical features].Acta Med Croatica. 2011;65(2):119-27. Acta Med Croatica. 2011. PMID: 22359877 Review. Croatian.
-
Angioedema Related to Angiotensin-Converting Enzyme Inhibitors: Attack Severity, Treatment, and Hospital Admission in a Prospective Multicenter Study.Medicine (Baltimore). 2015 Nov;94(45):e1939. doi: 10.1097/MD.0000000000001939. Medicine (Baltimore). 2015. PMID: 26559262 Free PMC article.
Cited by
-
Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic score.World Allergy Organ J. 2025 Mar 12;18(3):101037. doi: 10.1016/j.waojou.2025.101037. eCollection 2025 Mar. World Allergy Organ J. 2025. PMID: 40151541 Free PMC article.
-
Long-COVID and loss of smell: A post-COVID olfactory dysfunction that continues to challenge the allergist/immunologist.Allergy Asthma Proc. 2022 Mar 1;43(2):93-95. doi: 10.2500/aap.2022.43.220008. Allergy Asthma Proc. 2022. PMID: 35317885 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical